Citations (23)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Harun Patel, Azim Ansari, Rahul Pawara, Iqrar Ansari, Harsha Jadhav & Sanjay Surana. (2018) Design and synthesis of novel 2,4-disubstituted aminopyrimidines: reversible non-covalent T790M EGFR inhibitors. Journal of Receptors and Signal Transduction 38:5-6, pages 393-412.
Read now
Read now
Antonio Passaro, Enrico Cortesi & Filippo de Marinis. (2011) Second-line treatment of non-small-cell lung cancer: chemotherapy or tyrosine kinase inhibitors?. Expert Review of Anticancer Therapy 11:10, pages 1587-1597.
Read now
Read now
Articles from other publishers (21)
Tadayuki Nakashima, Yoshimasa Shiraishi, Ayaka Shiota, Yasuto Yoneshima, Eiji Iwama, Kentaro Tanaka & Isamu Okamoto. (2023) Afatinib-induced bronchiolitis obliterans. Current Problems in Cancer: Case Reports 10, pages 100231.
Crossref
Crossref
Meredith S. Eno, Jason D. Brubaker, John E. Campbell, Chris De Savi, Timothy J. Guzi, Brett D. Williams, Douglas Wilson, Kevin Wilson, Natasja Brooijmans, Joseph Kim, Ayşegül Özen, Emanuele Perola, John Hsieh, Victoria Brown, Kristina Fetalvero, Andrew Garner, Zhuo Zhang, Faith Stevison, Rich Woessner, Jatinder Singh, Yoav Timsit, Caitlin Kinkema, Clare Medendorp, Christopher Lee, Faris Albayya, Alena Zalutskaya, Stefanie Schalm & Thomas A. Dineen. (2022) Discovery of BLU-945, a Reversible, Potent, and Wild-Type-Sparing Next-Generation EGFR Mutant Inhibitor for Treatment-Resistant Non-Small-Cell Lung Cancer. Journal of Medicinal Chemistry 65:14, pages 9662-9677.
Crossref
Crossref
Fan Zhang, Jia Wang, Xiaobo Wang, Nan Wei, Haiyang Liu & Xiaoju Zhang. (2019) CD146‐mediated acquisition of stemness phenotype enhances tumour invasion and metastasis after EGFR‐TKI resistance in lung cancer. The Clinical Respiratory Journal 13:1, pages 23-33.
Crossref
Crossref
Harun M. Patel, Rahul Pawara, Azim Ansari, Malleshappa Noolvi & Sanjay Surana. (2017) Design and synthesis of quinazolinones as EGFR inhibitors to overcome EGFR resistance obstacle. Bioorganic & Medicinal Chemistry 25:10, pages 2713-2723.
Crossref
Crossref
Ádám Nagy, Lőrinc Sándor Pongor, András Szabó, Mariacarmela Santarpia & Balázs Győrffy. (2017) KRAS driven expression signature has prognostic power superior to mutation status in non-small cell lung cancer. International Journal of Cancer 140:4, pages 930-937.
Crossref
Crossref
Yan Chen, Wandan Huang, Feiyu Chen, Guoping Hu, Fenglei Li, Jianhua Li & Aiguo Xuan. (2016) Pregnane X receptors regulate CYP2C8 and P-glycoprotein to impact on the resistance of NSCLC cells to Taxol. Cancer Medicine 5:12, pages 3564-3571.
Crossref
Crossref
Vishal Boolell, Muhammad Alamgeer, David Watkins & Vinod Ganju. (2015) The Evolution of Therapies in Non-Small Cell Lung Cancer. Cancers 7:3, pages 1815-1846.
Crossref
Crossref
Christina M. Annunziata & Phillip A. Dennis. 2014. Handbook of Anticancer Pharmacokinetics and Pharmacodynamics. Handbook of Anticancer Pharmacokinetics and Pharmacodynamics
1
21
.
A.R. Abdul Razak, D. Soulières, S.A. Laurie, S.J. Hotte, S. Singh, E. Winquist, S. Chia, C. Le Tourneau, P.- F. Nguyen-Tan, E.X. Chen, K.K. Chan, T. Wang, N. Giri, C. Mormont, S. Quinn & L.L. Siu. (2013) A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck. Annals of Oncology 24:3, pages 761-769.
Crossref
Crossref
Xiaofei Wang & Baohui Han. (2013) Advances in Lung Cancer and Treatment Research. Journal of Cancer Therapy 04:08, pages 36-43.
Crossref
Crossref
Jiao Yang, Li-Jiao Wang, Jing-Jing Liu, Lei Zhong, Ren-Lin Zheng, Yong Xu, Pan Ji, Chun-Hui Zhang, Wen-Jing Wang, Xing-Dong Lin, Lin-Li Li, Yu-Quan Wei & Sheng-Yong Yang. (2012)
Structural Optimization and Structure–Activity Relationships of
N
2
-(4-(4-Methylpiperazin-1-yl)phenyl)-
N
8
-phenyl-9
H
-purine-2,8-diamine Derivatives, a New Class of Reversible Kinase Inhibitors Targeting both EGFR-Activating and Resistance Mutations
. Journal of Medicinal Chemistry 55:23, pages 10685-10699.
Crossref
Crossref
Philip T. CagleTimothy Craig Allen. (2012) Lung Cancer Genotype-Based Therapy and Predictive Biomarkers: Present and Future. Archives of Pathology & Laboratory Medicine 136:12, pages 1482-1491.
Crossref
Crossref
Sharon L. Longo, David J. Padalino, Sandra McGillis, Kirstin Petersen, Hartmut Schirok, Oliver Politz, Gregory W. Canute & Dawn E. Post. (2011) Bay846, a new irreversible small molecule inhibitor of EGFR and Her2, is highly effective against malignant brain tumor models. Investigational New Drugs 30:6, pages 2161-2172.
Crossref
Crossref
Deme John Karikios & Michael Joseph Boyer. (2012) Irreversible EGFR inhibitors in advanced non-small-cell lung carcinoma: rationale and clinical evidence. Clinical Investigation 2:3, pages 317-325.
Crossref
Crossref
Giulio Metro & Lucio Crinò. 2012. Biotargets of Cancer in Current Clinical Practice. Biotargets of Cancer in Current Clinical Practice
93
114
.
Carlos García-echeverría. 2011. Kinase Drug Discovery. Kinase Drug Discovery
286
302
.
Tony S. K. Mok. (2011) Personalized medicine in lung cancer: what we need to know. Nature Reviews Clinical Oncology 8:11, pages 661-668.
Crossref
Crossref
. (2011) Current World Literature. Current Opinion in Pulmonary Medicine 17:4, pages 292-295.
Crossref
Crossref
Moira Davenport & Mary Ann Howland. 2011. Challenging and Emerging Conditions in Emergency Medicine. Challenging and Emerging Conditions in Emergency Medicine
158
183
.
Daniel I. PerezValle PalomoConcepción PérezCarmen GilPablo D. DansF. Javier LuqueSantiago CondeAna Martínez. (2011) Switching Reversibility to Irreversibility in Glycogen Synthase Kinase 3 Inhibitors: Clues for Specific Design of New Compounds. Journal of Medicinal Chemistry 54:12, pages 4042-4056.
Crossref
Crossref
Chandra P. Belani. 2011. Advances in Radiation Oncology in Lung Cancer. Advances in Radiation Oncology in Lung Cancer
247
266
.